Open-label, randomized parallel group trial on the efficacy and safety of intra-articular administration of bevacizumab for knee osteoarthritis.

Open-label, randomized parallel group trial on the efficacy and safety of intra-articular administration of bevacizumab for knee osteoarthritis. - Trial for the efficacy and safety of bevacizumab for knee osteoarthritis.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008260

Enrollment

100

Registered

2012-07-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of knee joints

Interventions

Intra-articular administration of bevacizumab Intra-articular administration of sodium hyaluronate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Primary knee osteoarthritis with significant symptoms. 2. Aged 50 years or older. 3. Obtainment of informed consent in writing.

Exclusion criteria

Exclusion criteria: 1. Patients who do not have any significant physical, neurological, or mental problems. 2. Patients who do not have any significant disorders in motor systems. 3. Patients who are inadequate to enter the trial by physicians' judgments

Design outcomes

Primary

Measure	Time frame
Evaluation of the symptoms before and after the administration of bevacizumab.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026